 |
More: HIV Management 2008: The New York Course NY Course 2008: Progress in Antiretroviral Therapy CME April 24 - 25, 2008, New York, NY Author Information and Disclosures This activity was developed in collaboration with HIV Management 2008: The New York Course.
HIV Management 2008: The New York Course is an online educational collaboration between Albert Einstein College of Medicine and Medscape
Release Date: May 30, 2008; Valid for credit through May 30, 2009 | Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Legal DisclaimerThe materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. The materials presented here were prepared by independent authors under the editorial supervision of Medscape and were developed in collaboration with the HIV Management 2008: The New York Course. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Compare the potency of initial therapeutic options
- Define strategies for managing treatment-experienced patients
- Compare the potency of second-line therapeutic options
- Define what constitutes a
treatment-experienced patient
- Advise on the design of regimens for treatment-experienced patients with multiclass drug resistance
- Understand details of interpreting HIV resistance assays, including NRTI, NNRTI, PI, and tropism assays
- Identify some of the short-and long-term toxicities associated with use of current antiretroviral therapy
- Gain knowledge of how to manage or avoid some of these
toxicities
- Discuss the impact of toxicities on antiretroviral treatment outcomes
Authors and Disclosures Eric S. Daar, MD
Disclosure: Eric S. Daar, MD, has disclosed that he has received grants and/or research support from Abbott, Boehringer Ingelheim, Gilead, GlaxoSmithKline, and Merck. Dr. Daar has also disclosed that he
has served on the speaker's bureau for and that he has served as a consultant to Abbott, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Bristol-Myers Squibb, Pfizer, Tibotec, and Monogram. Richard H. Haubrich, MD
Disclosure: Richard H. Haubrich, MD, has disclosed that he has received grants and/or research support from GlaxoSmithKline, Pfizer, and Tibotec. Dr. Haubrich has also disclosed that he has served on
the speaker's bureau for Abbott, Gilead, Boehringer Ingelheim, and Roche, and that he has served as a consultant to Monogram. Sharon L. Walmsley, MD, MSc
Disclosure: Sharon L. Walmsley, MD, MSc, has disclosed that she has served as a consultant to Roche, Abbott, Boehringer Ingelheim, Tibotec, GlaxoSmithKline, and Bristol-Myers Squibb. Dr. Walmsley has also disclosed that she has served on the speaker's bureau
for Roche, Abbott, Boehringer Ingelheim, Tibotec, and GlaxoSmithKline, and that she has received grants and/or research support from Boehringer Ingelheim. |
 |
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. All other healthcare professionals completing continuing education credit for this activity will be issued a certificate of participation.
Albert Einstein College of Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
